文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌治疗反应评估中的PSMA PET/CT应用

Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
PubMed 文献 · J Nucl Med · 2025-07-01

本文综述了前列腺癌PSMA靶向PET/CT在治疗反应评估中的应用现状,指出传统影像和现有标准评估方法不适用于前列腺癌反应评估,PSMA PET进展标准与RECIP 1.0在放射性配体治疗等场景中有预后价值,但在雄激素信号轴靶向治疗中作用尚不明确,机器学习和人工智能可能有助于识别基于PSMA摄取变化的影像生物标志物。

要点

  • 常规影像(骨扫描、CT)在多种临床场景中不足以识别前列腺癌病灶。
  • 基于常规影像或缺乏前列腺癌敏感性的PET示踪剂的现有标准评估方法不适用于前列腺癌治疗反应评估。
  • PSMA PET进展标准与RECIP 1.0在PSMA靶向放射性药物治疗等场景中显示有价值和预后信息,但在雄激素信号轴靶向治疗中作用尚不明确。

核心结论

  • PSMA PET在前列腺癌初始分期、复发和PSMA靶向放射性药物治疗资格认定方面已获监管批准,但尚无用于治疗反应评估的专门监管批准。
  • PSMA PET进展标准和RECIP 1.0在PSMA靶向放射性药物治疗及其他细胞毒性治疗背景下显示有价值和预后信息,但在雄激素信号轴靶向治疗患者中作用尚不明确。
  • 机器学习和人工智能可能有助于识别基于治疗期间PSMA PET摄取变化的影像生物标志物。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 常规影像包括骨扫描和CT在多种临床场景中不足以识别前列腺癌病灶。
  • 基于常规影像或缺乏前列腺癌敏感性的PET示踪剂的现有标准评估方法不适用于前列腺癌治疗反应评估。
  • PSMA PET进展标准和RECIP 1.0在PSMA靶向放射性药物治疗及其他细胞毒性治疗背景下显示有价值和预后信息。
  • 在雄激素信号轴靶向治疗患者中,由于PSMA表达变化不定,上述标准的作用尚不明确。

关键数值与推荐

  • 原文未报告具体推荐条款或数值标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)-targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there have been regulatory approvals for PSMA PET for purposes of initial staging, recurrence, and establishing eligibility for PSMA-targeted radiopharmaceutical therapy. Conventional imaging modalities, including bone scan and CT, are inadequate for identifying sites of PC in a variety of clinical scenarios. Further, current standardized response assessment approaches based on either conventional imaging or PET radiotracers that lack sensitivity for PC are inappropriate for response assessment in men with PC. There is currently no specific regulatory approval for the use of PSMA PET for response assessment. In the context of the use of PSMA-targeted radiopharmaceutical therapy and other cytotoxic therapeutic approaches, both the PSMA PET progression criteria and RECIP 1.0 have been shown to have value and to provide prognostic information. However, the role of those criteria is less clear for patients who are being treated with agents targeting the androgen signaling axis, given variable changes in PSMA expression. Ultimately, there may be key roles for machine learning and artificial intelligence in identifying imaging biomarkers based on changes in PSMA PET uptake during therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gafita A, Schroeder JA, Ceci F, et al. Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT. J Nucl Med. 2025. PMID: 40473460. doi:10.2967/jnumed.124.268071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。